Search for other papers by Elisa Minaldi in
Google Scholar
PubMed
Search for other papers by Virginia Cappagli in
Google Scholar
PubMed
Search for other papers by Loredana Lorusso in
Google Scholar
PubMed
Search for other papers by Laura Valerio in
Google Scholar
PubMed
Search for other papers by Carlotta Giani in
Google Scholar
PubMed
Search for other papers by Matilde Viglione in
Google Scholar
PubMed
Search for other papers by Laura Agate in
Google Scholar
PubMed
Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients . Best Practice and Research. Clinical Endocrinology and Metabolism 2017 31 349 – 361 ( https://doi.org/10.1016/j.beem.2017.04.012 ) 8 National Institutes of Health
Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal
Abel Salazar Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal
Search for other papers by Sule Canberk in
Google Scholar
PubMed
Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal
Search for other papers by Joana C. Ferreira in
Google Scholar
PubMed
Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal
Department of Pathology, Faculty of Medicine of the University of Porto (FMUP), Porto, Portugal
Search for other papers by Luísa Pereira in
Google Scholar
PubMed
Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal
Search for other papers by Rui Batısta in
Google Scholar
PubMed
Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal
Search for other papers by Andre F. Vieira in
Google Scholar
PubMed
Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal
Department of Pathology, Faculty of Medicine of the University of Porto (FMUP), Porto, Portugal
Search for other papers by Paula Soares in
Google Scholar
PubMed
Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal
Department of Pathology, Faculty of Medicine of the University of Porto (FMUP), Porto, Portugal
Abel Salazar Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal
Department of Pathology and Oncology, Centro Hospitalar São João, Porto, Portugal
Search for other papers by Manuel Sobrinho Simões in
Google Scholar
PubMed
Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal
Department of Pathology, Faculty of Medicine of the University of Porto (FMUP), Porto, Portugal
Search for other papers by Valdemar Máximo in
Google Scholar
PubMed
occur sporadically, but 3–9% are defined as familial non-medullary thyroid cancer (FNMTC). Less than 5% of FNMTC is seen in syndromic forms associated with well-defined driver germline alterations. This rare type of FNMTC includes Cowden syndrome
Search for other papers by Elen Dias Accordi in
Google Scholar
PubMed
Search for other papers by Paraskevi Xekouki in
Google Scholar
PubMed
Search for other papers by Bruna Azevedo in
Google Scholar
PubMed
Search for other papers by Rodrigo Bertollo de Alexandre in
Google Scholar
PubMed
Álvaro Center for Analysis and Clinical Research - Diagnósticos da América (DASA), Cascavel, Brazil
Search for other papers by Carla Frasson in
Google Scholar
PubMed
Search for other papers by Siliane Marie Gantzel in
Google Scholar
PubMed
Search for other papers by Georgios Z. Papadakis in
Google Scholar
PubMed
Search for other papers by Anna Angelousi in
Google Scholar
PubMed
Search for other papers by Constantine A. Stratakis in
Google Scholar
PubMed
Search for other papers by Vanessa Santos Sotomaior in
Google Scholar
PubMed
Section on Endocrinology and Genetics, Program on Developmental Endocrinology and Genetics (PDEGEN) and Pediatric Endocrinology Inter-Institute Training Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)
Search for other papers by Fabio R. Faucz in
Google Scholar
PubMed
females [ 3 ]. There are two types of endocrine thyroid cells from which thyroid cancers are derived: follicular thyroid cells and parafollicular C cells [ 4 ]. Medullary thyroid cancers that are parafollicular thyroid C cells in origin have been
Search for other papers by Cosimo Durante in
Google Scholar
PubMed
Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed
Search for other papers by Agnieszka Czarniecka in
Google Scholar
PubMed
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
Search for other papers by Gilles Russ in
Google Scholar
PubMed
Search for other papers by Fernando Schmitt in
Google Scholar
PubMed
Search for other papers by Paula Soares in
Google Scholar
PubMed
Search for other papers by Tamas Solymosi in
Google Scholar
PubMed
Search for other papers by Enrico Papini in
Google Scholar
PubMed
case of personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 ( 27 ). Cut-off points to separate non-medullary reasons for increased calcitonin from medullary thyroid carcinoma have been established (>30 pg/mL in
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Search for other papers by Daniele Ceruti in
Google Scholar
PubMed
Search for other papers by Massimiliano Succi in
Google Scholar
PubMed
Search for other papers by Simone De Leo in
Google Scholar
PubMed
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Matteo Trevisan in
Google Scholar
PubMed
Search for other papers by Claudia Moneta in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Introduction Tyrosine kinase inhibitors (TKIs) and target therapies are efficiently used in the treatment of progressive radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) and advanced medullary thyroid cancer (MTC) ( 1 ). In
Search for other papers by Minoru Kihara in
Google Scholar
PubMed
Search for other papers by Akira Miyauchi in
Google Scholar
PubMed
Search for other papers by Hiroshi Yoshida in
Google Scholar
PubMed
Search for other papers by Osamu Yamada in
Google Scholar
PubMed
Search for other papers by Hiroo Masuoka in
Google Scholar
PubMed
Search for other papers by Tomonori Yabuta in
Google Scholar
PubMed
Search for other papers by Takuya Higashiyama in
Google Scholar
PubMed
Search for other papers by Mitsuhiro Fukushima in
Google Scholar
PubMed
Search for other papers by Yasuhiro Ito in
Google Scholar
PubMed
Search for other papers by Kaoru Kobayashi in
Google Scholar
PubMed
Search for other papers by Akihiro Miya in
Google Scholar
PubMed
.1002/hed.23241 23468374 13 American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr: Medullary thyroid cancer: management guidelines of
Department of Medicine, Endocrinology Service, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil
Search for other papers by Fernanda Andrade in
Google Scholar
PubMed
Search for other papers by Danielle Probstner in
Google Scholar
PubMed
Search for other papers by Marcus Decnop in
Google Scholar
PubMed
Search for other papers by Daniel Bulzico in
Google Scholar
PubMed
Search for other papers by Denise Momesso in
Google Scholar
PubMed
Department of Medicine, Endocrinology Service, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil
Search for other papers by Rossana Corbo in
Google Scholar
PubMed
Search for other papers by Mario Vaisman in
Google Scholar
PubMed
Department of Medicine, Endocrinology Service, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil
Search for other papers by Fernanda Vaisman in
Google Scholar
PubMed
selection of patients included in the analysis. MTC, medullary thyroid cancer; ZA, zoledronic acid; SRE, skeletal related events. In this study, as a referral cancer center, we found that the bone metastases were usually present at diagnosis and
Search for other papers by Giorgio Grani in
Google Scholar
PubMed
Search for other papers by Livia Lamartina in
Google Scholar
PubMed
Search for other papers by Valeria Ramundo in
Google Scholar
PubMed
Search for other papers by Rosa Falcone in
Google Scholar
PubMed
Search for other papers by Cristiano Lomonaco in
Google Scholar
PubMed
Search for other papers by Laura Ciotti in
Google Scholar
PubMed
Search for other papers by Martina Barone in
Google Scholar
PubMed
Search for other papers by Marianna Maranghi in
Google Scholar
PubMed
Search for other papers by Vito Cantisani in
Google Scholar
PubMed
Search for other papers by Sebastiano Filetti in
Google Scholar
PubMed
Search for other papers by Cosimo Durante in
Google Scholar
PubMed
-variant papillary thyroid cancer ( n = 6); medullary thyroid cancer ( n = 2); papillary thyroid cancer ( n = 26); and metastases from other solid tumors ( n = 3). The other 3 nodules had cytological diagnoses of malignancy (TIR5, n = 1) or suspected malignancy
Search for other papers by Marta Di Stefano in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Search for other papers by Simone De Leo in
Google Scholar
PubMed
Search for other papers by Michela Perrino in
Google Scholar
PubMed
Search for other papers by Mauro Viganò in
Google Scholar
PubMed
Department of Clinical Sciences and Community Health, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
symptomatic, advanced or metastatic medullary thyroid cancer . J Clin Oncol . 2009 ; 27 ( 23 ): 3794 – 801 . http://dx.doi.org/10.1200/JCO.2008.18.7815 12 Sherman SI , Wirth LJ , Droz JP , Hofmann M , Bastholt L , Martins RG
Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia
Search for other papers by Ayanthi Wijewardene in
Google Scholar
PubMed
Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia
Search for other papers by Matti Gild in
Google Scholar
PubMed
Search for other papers by Carolina Nylén in
Google Scholar
PubMed
Nuclear Medicine Department, Royal North Shore Hospital, Sydney, New South Wales, Australia
Search for other papers by Geoffrey Schembri in
Google Scholar
PubMed
Nuclear Medicine Department, Royal North Shore Hospital, Sydney, New South Wales, Australia
Search for other papers by Paul Roach in
Google Scholar
PubMed
Nuclear Medicine Department, Royal North Shore Hospital, Sydney, New South Wales, Australia
Search for other papers by Jeremy Hoang in
Google Scholar
PubMed
Search for other papers by Ahmad Aniss in
Google Scholar
PubMed
Endocrine Surgery Department, Royal North Shore Hospital, Sydney, New South Wales, Australia
Search for other papers by Anthony Glover in
Google Scholar
PubMed
Endocrine Surgery Department, Royal North Shore Hospital, Sydney, New South Wales, Australia
Search for other papers by Mark Sywak in
Google Scholar
PubMed
Endocrine Surgery Department, Royal North Shore Hospital, Sydney, New South Wales, Australia
Search for other papers by Stan Sidhu in
Google Scholar
PubMed
Search for other papers by Diana Learoyd in
Google Scholar
PubMed
Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia
Search for other papers by Bruce Robinson in
Google Scholar
PubMed
Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia
Search for other papers by Lyndal Tacon in
Google Scholar
PubMed
Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia
Search for other papers by Roderick Clifton-Bligh in
Google Scholar
PubMed
thyroid cancer were excluded, along with lymphoma of the thyroid gland. RAI activities were categorized into 3 groups: low (<1.3 GBq, 35 mCi), intermediate (1.3–3.74 GBq; 35–101 mCi), and high (≥3.75 GBq; 101 mci). The high-activity group was further